FIELD: medicine.
SUBSTANCE: there are presented versions of a humanised monoclonal antibody to hepatocyte growth factor. What is described is a cell line producing the antibody. There are offered a pharmaceutical composition and a method of treating tumours on the basis of the antibody, as well as using the antibody for producing a drug for treating a malignant growth.
EFFECT: new neutralising antibody to hepatocyte growth factor that can find application in treating cancer in an individual.
8 cl, 8 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 | 2009 |
|
RU2546254C9 |
| MONOCLONAL ANTIBODIES TO HEPATOCYTE GROWTH FACTOR | 2004 |
|
RU2361879C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) | 2003 |
|
RU2303461C9 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
